MR
Martin Reck-Deppermann
Elite in Non-Small Cell Lung Cancer (NCSLC)
Check Martin Reck-Deppermann's experience treating your condition:
About Martin Reck-Deppermann

Martin Reck-Deppermann practices in Grosshansdorf, Germany. Reck-Deppermann is rated as an Elite expert by MediFind in the treatment of Non-Small Cell Lung Cancer (NCSLC). They are also highly rated in 17 other conditions, according to our data. Their top areas of expertise are Non-Small Cell Lung Cancer NCSLC, Lung Cancer, EGFR Positive Lung Cancer, Endoscopy, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 372 peer reviewed articles and participating in 17 clinical trials in the past 15 years. In particular, they have co-authored 276 articles and participated in 12 clinical trials in the study of Non-Small Cell Lung Cancer (NCSLC).

Locations
Lung Clinic Grosshansdorf-department Of Thoracic Oncology, Grosshansdorf, 22927, DE
Other Locations
Krankenhaus Großhansdorf, Großhansdorf, 22927, DE
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


16 Clinical Trials

A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
Single-Arm Phase II-Study in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) With Poor Performance Status Receiving Atezolizumab-Carboplatin-Etoposide
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Multicentre Randomised Phase II Trial of Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients (=/> 70 Years) With Advanced Non-Small Cell Lung Cancer
A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy
Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology - An AIO Phase Ib Trial
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
View 8 Less Clinical Trials -

372 Total Publications

Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography.


Save this expert for later
Sign Up
Looking for the best expert for you?
Start Here
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more